AQP4 and neuromyelitis optica: Up to 40% of patients with NMO, recurrent LETM or recurrent optic neuritis are anti-AQP4-seronegative upon disease onset and during the course of the disease [100] and anti-AQP4 antibodies are present in the serum of 70–90% of patients with NMOSD.